International Journal of Radiation Oncology * Biology * Physics
Volume 49, Issue 2 , Pages 311-318 , 1 February 2001

From translational research to improved local control and survival: the Gilbert Fletcher award lecture, Lugano, March 2000

Presented at ICTR 2000, Lugano, Switzerland, March 5–8, 2000.

  • Harry Bartelink, M.D., Ph.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Prof. H. Bartelink, Department of Radiotherapy, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

,Accepted 31 August 2000.

References 

  1. Bartelink H, Kallman FR, Rapacchietta D, et al.  Therapeutic enhancement in mice by clinically relevant dose and fractionations schedules of CDDP and irradiation. Radiother Oncol. 1986;6:61–74
  2. Schaake-Koning C, Van den Bogaert W, Dalesio O, et al.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 1992;326:524–530
  3. Thomas GM. Improved treated for cervical cancer. N Engl J Med. 1999;340(15):1190–1200
  4. Pignon JP, Bourhis J, Domenge C, Désigné L, on behalf of the MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 2000;355:949–955.
  5. Calais G, Alfonsi M, Bardet E, et al.  Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91(24):2081–2086
  6. Bartelink H, Begg AC, Coco Martin J, et al.  Translational reserch offers individually tailored treatments for cancer patients. Cancer J Sci Am. 2000;6(1):2–10
  7. Robbins KT, Kumar P, Regine WF, et al.  Efficacy of targeted supradose cisplatin and concomitant radiation theray for advanced head and neck cancer (The Memphis experience). Int J Radiat Oncol Biol Phys. 1997;38(2):263–271
  8. Rasch C, Keus RB, Tan IB, et al.  Intra-arterial cisplatin, and concomitant radiation for advanced head, and neck cancer. Proceedings of the 41st Annual ASTRO Meeting 1999 (Abstr. 2189). Int J Radiat Biol Phys. 1999;45(Suppl. 3):375
  9. Begg AC. Cisplatin and radiation (interaction probabilities and therapeutic possibilities). Int J Radiat Oncol Biol Phys. 1990;19:1183–1189
  10. Terheggen PM, Dijkman R, Begg AC, et al.  Monitoring of interaction products of cis-diamminedichloroplatinum (II) and cis-diammine (1,1-cyclobutanedicarboxylato)platinum (II) with DNA in cells from platinum-treated cancer patients. Cancer Res. 1998;48:5597–5603
  11. Van de Vaart PJ, Belderbos J, De Jong D, et al.  DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin, and radiotherapy. Int J Cancer [Pred Oncol]. 2000;89:160–166
  12. Verheij M, Bartelink H. Radiation-induced apoptosis. Cell Tissue Res. 2000;301:133–142
  13. Ten Bokkel Huinink WW, Schornagel JH, Hilton A, et al.  Topical application of miltefosine against skin metastases of breast cancer. Proceedings of the 28th ASCO Meeting, 1992 (Abstr. 39). J Clin Oncol. 1992;11:53
  14. Julien JP, Bijker N, Fentiman IS, et al.  The role of radiotherapy in breast conserving treatment for ductal carcinoma in situ (First results of EORTC randomised phase III trial 10853). Lancet. 2000;355(9203):528–533
  15. Alizadeh AA, Eisen MB, Davis RE, et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511
  16. Perou CM, Jeffrey SS, Van de Rijn M, et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA. 1999;96:9212–9217
  17. Collette L, Fourquet A, Horiot JC; et al. Impact of a boost dose of 16 Gy on local control in patients with early breast cancer: the EORTC “boost versus no boost” trial. 19th ESTRO, September 19–23, 2000, Istanbul, Turkey (Abstr.). Radiother Oncol 2001. In press.
  18. Friend SH. How DNA microarrays and expression profiling will affect clinical practice. Br Med J. 1999;319(7220):1306–1307
  19. Bartelink H, Rubens RD, Van der Schueren E, et al.  Hormonal therapy prolongs survival in irradiated locally advanced breast cancer. A European Organization for Research and Treatment of Cancer (EORTC) randomized phase–III trial. J Clin Oncol. 1997;15:207–215
  20. Scottish Cancer Trials Breast Group, and ICRF Breast Cancer Unit, Guy’s Hospital, London . Adjuvant ovarian ablation versus CF chemotherapy I premenopausal women with pathological stage II breast carcinoma (The Scottish trial). Lancet. 1993;341:1293–1293
  21. Aebi S, Gelber S, Castiglione-Gertsch M, et al.  Treatment with chemotherapy alone is inadequate for very young women with estrogen receptor positive breast cancer. Results from the International Breast Cancer Study Group (IBCSG) Trials I, II, V and VI. Proceedings of 35th Annual ASCO meeting, 1999 (Abstr. 260). J Clin Oncol. 1999;18:69a
  22. Rutqvist LE. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer (a randomized study by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group and the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (GIVIO). Proceedings of 35th Annual ASCO meeting, 1999 (Abstr. 251)). J Clin Oncol. 1999;18:67
  23. Davidson N, O’Niell A, Vukov A, et al.  Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer (An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101). Proceedings of 35th Annual ASCO meeting, 1999 (Abstr. 249)). J Clin Oncol. 1999;18:67
  24. Jakesz R, Hausmaninger H, Samonigg H, et al.  Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients (Four year results of Austrian Breast Cancer Study Group (ASCSG) Trial 5. Proceedings of 35th Annual ASCO meeting, 1999 (Abstr. 250)). J Clin Oncol. 1999;18:67
  25. Bartelink H, Begg A, Coco Martin J, et al.  Towards prediction and modulation of treatment response. Radiother Oncol. 1999;50:1–11
  26. Enmark E, Pelto-Huikko M, Grandien K, et al.  Human estrogen receptor beta-gene structure, chromosomal localization and expression pattern. J Clin Endocrinol Metab. 1997;82(12):4258–4265
  27. Zwijsen RM, Wientjens E, Klompmaker R, et al.  CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997;88:405–415
  28. Zwijsen RM, Buckle RS, Hijmans EM, et al.  Ligant-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev. 1998;12:3488–3498

PII: S0360-3016(00)01499-1

International Journal of Radiation Oncology * Biology * Physics
Volume 49, Issue 2 , Pages 311-318 , 1 February 2001

Article Tools

* Image Usage & Resolution